Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
New England Journal of Medicine · 24.08.2023 · 389 (8) · 710-721
DOI: 10.1056/nejmoa2303810 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 24.08.2023. Verfasst von Adrian Sacher und 27 weiteren Autor:innen. Beteiligte Einrichtung: From the Princess Margaret Cancer Centre, University Health Network, and the Departments of Medicine and Immunology, University of Toronto, Toronto (…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 339-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Genentech.
Abstract (Originalsprache)
BACKGROUND: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. RESULTS: A total of 137 patients (60 with non-small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related deaths were reported. Treatment-related adverse events occurred in 127 patients (93%); grade 3 events occurred in 15 patients (11%) and a grade 4 event in 1 patient (1%). Treatment-related adverse events resulted in a dose reduction in 19 patients (14%) and discontinuation of treatment in 4 patients (3%). Among patients with NSCLC, a confirmed response was observed in 53.4% of patients (95% confidence interval [CI], 39.9 to 66.7), and the median progression-free survival was 13.1 months (95% CI, 8.8 to could not be estimated). Among patients with colorectal cancer, a confirmed response was observed in 29.1% of patients (95% CI, 17.6 to 42.9), and the median progression-free survival was 5.6 months (95% CI, 4.1 to 8.2). Responses were also observed in patients with other solid tumors. Serial assessment of circulating tumor DNA showed declines in KRAS G12C variant allele frequency associated with response and identified genomic alterations that may confer resistance to divarasib. CONCLUSIONS: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT04449874.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Princess Margaret Cancer Centre, University Health Network, and the Departments of Medicine and Immunology, University of Toronto, Toronto (A. Sacher), and the Lady Davis Institute and the Segal Cancer Center,…
ORCID-Profile: Neekesh V Dharia, Jayesh Desai
Förderung
- Genentech
Zitieren
APA
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., Bowyer, S., de Miguel, M., Han, S. W., Krebs, M. G., Lee, J. S., Cheng, M. L., Arbour, K., Massarelli, E., Choi, Y., …, & GO42144 Investigator and Study Group (2023). Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. New England Journal of Medicine, 389(8), 710-721. https://doi.org/10.1056/nejmoa2303810
Vancouver
Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. New England Journal of Medicine. 2023;389(8):710-721. doi:10.1056/nejmoa2303810
BibTeX
@article{Sacher2023,
author = {Sacher, Adrian and LoRusso, Patricia and Patel, Manish R and Miller, Wilson H and Garralda, Elena and Forster, Martin D and Santoro, Armando and Falcon, Alejandro and Kim, Tae Won and Paz-Ares, Luis and Bowyer, Samantha and de Miguel, Maria and Han, Sae-Won and Krebs, Matthew G and Lee, Jong-Seok and Cheng, Michael L and Arbour, Kathryn and Massarelli, Erminia and Choi, Yoonha and Shi, Zhen and Mandlekar, Sandhya and Lin, Mark T and Royer-Joo, Stephanie and Chang, Julie and Dharia, Neekesh V and Schutzman, Jennifer L and Desai, Jayesh and GO42144 Investigator and Study Group, GO42144 Investigator and Study Group},
title = {Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {8},
pages = {710--721},
doi = {10.1056/nejmoa2303810}
}
EUVIMED